To Get Help Now
Defective Drug Lawsuits
Click Here
 
Today's Date:

Johnson & Johnson Unit Slapped with $2.5 Million Judgment Over Allegations That the Drug Risperdal Causes Breast Growth in Men

A Johnson & Johnson (J&J) unit has been slapped with a $2.5 million judgment over allegations that the company failed to warn the family of an autistic boy and his doctors about the risks of hormonal imbalances and breast growth associated with the drug Risperdal.

A Philadelphia County Court of Common Pleas jury slammed Janssen Pharmaceuticals with the decision on Tuesday after hearing evidence that J&J’s Janssen Pharmaceuticals unit had spent years trying to cover up data that showed Risperdal could cause breast growth in adolescent males, known as gynecomastia. Thousands of product liability lawsuits over the drug are pending across the country. Tuesday’s verdict is the first, according to Law360. More Johnson & Johnson Unit Slapped with $2.5 Million Judgment Over Allegations That the Drug Risperdal Causes Breast Growth in Men

Federal Judge sets Yaz Birth Control Trial Date, Accuses Bayer of Trying to “Wear Everyone Down”

Judge sets Yaz Birth Control Trial Date

Judge sets Yaz Birth Control Trial Date


An Illinois federal judge overseeing the Yaz birth control multidistrict litigation (MDL) set a trial date on Friday for one of the suits in the litigation.

The MDL involves allegations that Bayer HealthCare Pharmaceuticals, Inc.’s Yaz birth control drug causes strokes. In an order viewed by Law360, U.S. District Judge David R. Herndon said that Bayer had failed to properly conduct analyses or negotiations in certain cases alleging the drugs cause blood clots. He said that he believed that Bayer’s strategy was one of “attrition,” and that it amounted to “wearing everyone down over time.” More Federal Judge sets Yaz Birth Control Trial Date, Accuses Bayer of Trying to “Wear Everyone Down”

Mass Tort Involving 75 Xarelto Cases is Created in Philadelphia

A mass tort has been organized in Philadelphia surrounding the blood-thinning drug Xarelto, which has been alleged to cause uncontrollable and sometimes fatal bleeding.

Approximately 75 Xarelto cases were transferred to the Philadelphia Court of Common Pleas’ Complex Litigation Center by the court’s Judge Kevin Dougherty. The lawsuits are filed against Johnson & Johnson (J&J) subsidiary Janssen Pharmaceuticals and Bayer HealthCare Pharmaceuticals, according to The Legal Intelligencer (The Legal). More Mass Tort Involving 75 Xarelto Cases is Created in Philadelphia

National Law Firm, Parker Waichman LLP, Seeks Increased Transparency and Ethics from the Pharmaceutical Industry in the New Year

In the new year, Parker Waichman LLP hopes for increased testing, safety, and efficacy in the processes and promotions used by Big Pharma so that consumers may be confident that they are receiving safe and effective medications that were ethically developed, tested, and marketed.

Parker Waichman, a national law firm that has long been an advocate for victims of defective medications is urging the pharmaceutical industry, as we approach a new year, to step up the ways in which it develops, tests, inspects, and markets medications.

In the new year, Parker Waichman is seeking increased transparency and accountability from all drug makers, with the hope that patient welfare is made the key priority and placed before drug approval activities and profits.
More National Law Firm, Parker Waichman LLP, Seeks Increased Transparency and Ethics from the Pharmaceutical Industry in the New Year

Women with Multiple Sclerosis who Have a Higher BMI are at Higher Risk for Lymphopenia, Studies Show

Researchers in Germany and Sweden have found that some female patients taking the multiple sclerosis (MS) drug Gilenya (fingolomid) may be at increased risk for lymphopenia, a condition that affects the immune system.

Lymphopenia (also known as lymphocytopenia) is a condition in which a patient has a deficiency of lymphocytes, which play a vital role in supporting immune system function. Gilenya has been known to reduce the level of circulating lymphocytes, and one of the most common side effects of the drug reported by the U.S. Food and Drug Administration (FDA) and the drug’s manufacturer, Novartis Pharma Stein AG, is infections. Lower lymphocyte numbers make the patient more susceptible to infection, according to EmaxHealth.com. More Women with Multiple Sclerosis who Have a Higher BMI are at Higher Risk for Lymphopenia, Studies Show

Beta-Blockers Linked to Premature Death in Dialysis Patients

A new study published in an upcoming issue of the Journal of the American Society of Nephrology found that dialysis patients who take beta-blockers that can be easily removed from the blood through dialysis may be at an increased risk of premature death compared with patients whose heart medications are more difficult to remove.

A group of drugs known as beta-blockers lower the risk of premature death in heart patients not on dialysis, but the medications – used to treat angina, reduce high blood pressure and control heart rhythm – increase the risk of premature death in dialysis patients. Experts say the filtering effects of dialysis remove the beta-blockers from circulation, leaving patients unable to experience their full benefit, according to MedicalXpress.com. More Beta-Blockers Linked to Premature Death in Dialysis Patients

Parents, Beware of Topical Teething Anesthetics

Topical anesthetics containing Lidocaine Viscous are popular with parents trying sooth their little ones’ teething pain, but the medications can seriously injure, even kill, young patients.

In June, the U.S. Food and Drug Administration (FDA) warned against use of the products, particularly those containing more than 2 percent Lidocaine Viscous. The FDA said that it would require a new Boxed Warning, the FDA’s strongest warning, to all packages of the numbing agents. More Parents, Beware of Topical Teething Anesthetics

Hospira Receives FDA Warning for Drug Manufacturing Violations

The Food and Drug Administration has sent a warning letter to Hospira Inc. over “significant violations” of current good manufacturing practice (CGMP). The FDA said the company has not taken adequate steps to correct the violations, which include “visible particles” in lots of a chemotherapy drug.

In an inspection conducted from February 24 to March 1, 2014 at Hospira’s manufacturing facility in Mulgrave, Australia, FDA inspectors discovered “visible particles” in an injectable drug, The Chicago Tribune reports. The company said it is considering what corrective actions it needs to take but said it intends to respond fully to the warning letter. At this time, the FDA is not restricting the production or shipment of pharmaceutical products from the Mulgrave plant, but could do so if the violations are not corrected. More Hospira Receives FDA Warning for Drug Manufacturing Violations

Billions Paid to Doctors by Drug Firms and Medical Device Makers

Records released this week under a provision of the Affordable Care Act reveal that drug makers and medical device companies paid at least $3.5 billion to doctors and teaching hospitals during the final five months of 2013.

The Physician Payments Sunshine Act, part of the 2010 health care law, requires drug makers and manufacturers of medical devices to disclose payments to physicians and teaching hospitals, The Wall Street Journal reports. The Centers for Medicare and Medicaid Services compiled the records into a database posted online on Tuesday. CMS said about 40 percent of the payment records will not identify the recipients because of data problems. More Billions Paid to Doctors by Drug Firms and Medical Device Makers

New Jersey Man Alleges Eli Lilly Testosterone Replacement Product Caused Him a Heart Attack

Drug maker Eli Lilly is facing a lawsuit filed by a New Jersey man in federal court in Newark over the company’s testosterone replacement drug Axiron.

According to the lawsuit, the patient stated that he began taking Axiron at age 54 in September 2012 and suffered a heart attack on October 3, 2012. Had the patient known that Axiron could increase users’ risk for heart attack, he would not have started taking it, the suit states. More New Jersey Man Alleges Eli Lilly Testosterone Replacement Product Caused Him a Heart Attack